Skip to content

Stereotactic Body Radiotherapy (SBRT) for Reirradiation of Inoperable Lung Lesions

Stereotactic Body Radiotherapy (SBRT) for Reirradiation of Inoperable Lung Lesions: an Italian Multicenter Retrospective Analysis (STRILL IT)

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT07401615
Enrollment
150
Registered
2026-02-10
Start date
2024-11-25
Completion date
2026-12-01
Last updated
2026-02-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non Small Cell Lung Cancer, Pulmonary Stereotactic Radiotherapy

Keywords

non small cell lung cancer, pulmonary stereotactic radiotherapy, sbrt, re-irradiation

Brief summary

Radiotherapy (radiation treatment) is often used to treat lung cancers and lung tumors that have spread from other cancers. It can be very effective, especially in early-stage lung cancer or when there are only a few tumor sites. Even so, some patients later develop a local recurrence, meaning the cancer comes back in the same area that was previously treated with radiation. When this happens, treatment options are limited. Surgery can sometimes remove the recurrent tumor, but many patients are not able to have surgery because of their general health or because the tumor is difficult to remove. For these patients, a second course of radiotherapy (called re-irradiation) may be the only possible treatment. One type of radiotherapy, called stereotactic body radiotherapy (SBRT), delivers very high doses of radiation very precisely. SBRT has been used successfully as a second treatment after standard radiotherapy in some patients. However, there is very little information about using SBRT again in patients who already received SBRT the first time. Because only small studies have been done and the patients were very different from each other, doctors still do not know enough about how safe and effective a second SBRT treatment is. In particular, it is still unclear whether giving another high-dose radiation treatment is possible without causing serious side effects. More research is needed to better understand this option and help guide treatment decisions for patients.

Interventions

None listed

Sponsors

Istituto Clinico Humanitas
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Inoperable primary non-small cell lung cancer or other metastatic primaries with lung metastases, already treated with radical dose SBRT * Inoperable local recurrence (defined as a tumor recurrence overlapping the 50% isodose field) confirmed by documented radiographic findings and/or pathological biopsies within the thoracic area * Patients had previously received curative intent SBRT with a biologically equivalent dose equal or higher than 75 Gy * Stereotactic reirradiation with ablative purposes up to 8 fractions * No active distant metastasis or controlled distant metastasis at the time of re-irradiation * More than 12 months from previous SBRT * PS ≤ 2

Exclusion criteria

* Previous conventional RT * Reirradiation with palliative doses * Reirradiation with conventionally fractionated or mildly hypofractionated RT

Design outcomes

Primary

MeasureTime frameDescription
Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]from treatment to 1 years follow upevaluation of treatment safety through toxicities according to the CACTE scale

Secondary

MeasureTime frameDescription
Number of partecipant with local controlfrom enrollment to 1 years follow updefined as the absence of progression within the field of SABR, assessed by contrast-enhanced CT scan
Time to new systemic treatmentfrom enrollment to 1 years follow uptime from the first day of SBRT to change or starting of new systemic therapies
Progression free survivalfrom enrollment to 1 years follow uptime from the first day of SABR until the date of detection of progressive disease (in-field or out-field) or death, whichever occurred first.
Overall survivalfrom enrollment to 1 years follow uptime from the first day of SABR to death. Patients lost to follow-up have their OS censored at the last date they were known to be alive
Dosimetric parameters related to treatment toxicityfrom enrollment to 1 years follow upanalysis between correlation between treatment dosage and occurrence of toxicity

Countries

Italy

Contacts

CONTACTDavide Franceschini, MD, radiation oncologist
davide.franceschini@cancercenter.humanitas.it+39 0282247428
CONTACTLaura Bonavita, master degree
laura.bonavita@humanitas.it+39 0282247026

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 14, 2026